ロード中...
CDK9 inhibitors in acute myeloid leukemia
Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregul...
保存先:
| 出版年: | J Exp Clin Cancer Res |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5824552/ https://ncbi.nlm.nih.gov/pubmed/29471852 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-018-0704-8 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|